These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

500 related items for PubMed ID: 2874213

  • 1. Activation of DA1 receptors by dopamine or fenoldopam increases cyclic AMP levels in the renal artery but not in the superior cervical ganglion of the rat.
    Alkadhi KA, Sabouni MH, Ansari AF, Lokhandwala MF.
    J Pharmacol Exp Ther; 1986 Aug; 238(2):547-53. PubMed ID: 2874213
    [Abstract] [Full Text] [Related]

  • 2. Pharmacological characterization of dopamine receptors in the stellate ganglia with selective DA1 and DA2 receptor agonists and antagonists.
    Sabouni MH, Alkadhi KA, Lokhandwala MF.
    J Pharmacol Exp Ther; 1986 Jan; 236(1):65-70. PubMed ID: 2867216
    [Abstract] [Full Text] [Related]

  • 3. Effect of dopamine receptor activation on ganglionic transmission and cyclic AMP levels in the stellate ganglia and renal arteries of the dog.
    Sabouni MH, Alkadhi KA, Lokhandwala MF.
    J Pharmacol Exp Ther; 1987 Jan; 240(1):93-8. PubMed ID: 2879905
    [Abstract] [Full Text] [Related]

  • 4. Biochemical and pharmacological characterization of ganglionic dopamine receptors.
    Sabouni MH, Alkadhi KA, Lokhandwala MF.
    Clin Exp Hypertens A; 1987 Jan; 9(5-6):873-87. PubMed ID: 2887312
    [Abstract] [Full Text] [Related]

  • 5. The inhibition of ganglionic transmission via presynaptic dopamine DA1 and postsynaptic DA2 receptor activation in the canine cardiac sympathetic ganglia.
    Mukai M, Kushiku K, Yamada H, Yamada K, Dan K, Furukawa T.
    J Pharmacol Exp Ther; 1996 Nov; 279(2):822-9. PubMed ID: 8930189
    [Abstract] [Full Text] [Related]

  • 6. Pharmacological analysis of the actions of SKF 82526 on cardiovascular dopamine receptors.
    Lokhandwala MF, Watkins HO, Sabouni MH, Alkadhi KA.
    J Pharmacol Exp Ther; 1985 Aug; 234(2):337-44. PubMed ID: 2862275
    [Abstract] [Full Text] [Related]

  • 7. Vascular effects of selective dopamine receptor agonists and antagonists in the rat kidney.
    Schmidt M, Krieger JP, Giesen-Crouse EM, Imbs JL.
    Arch Int Pharmacodyn Ther; 1987 Apr; 286(2):195-205. PubMed ID: 2954515
    [Abstract] [Full Text] [Related]

  • 8. Characterization of the hypotensive action of dopamine receptor agonists fenoldopam and quinpirole in anaesthetized rats.
    Sengupta S, Lokhandwala MF.
    J Auton Pharmacol; 1985 Dec; 5(4):289-94. PubMed ID: 2869041
    [Abstract] [Full Text] [Related]

  • 9. Suppression of sympathetic ganglionic neurotransmission by the selective dopamine-1 receptor agonist fenoldopam (SK&F 82526) in the anesthetized dog.
    Shebuski RJ, Fujita T, Smith JM, Kopaciewicz LJ, Blumberg AL, Hieble JP.
    J Pharmacol Exp Ther; 1985 Dec; 235(3):735-40. PubMed ID: 2867207
    [Abstract] [Full Text] [Related]

  • 10. Effects of alpha adrenoceptor and dopamine receptor agonists and antagonists on ganglionic transmission.
    Satoh Y, Kohli JD, Goldberg LI.
    J Pharmacol Exp Ther; 1989 Oct; 251(1):253-7. PubMed ID: 2571718
    [Abstract] [Full Text] [Related]

  • 11. Characterization of dopamine receptors mediating inhibition of adenylate cyclase activity in rat striatum.
    Onali P, Olianas MC, Gessa GL.
    Mol Pharmacol; 1985 Aug; 28(2):138-45. PubMed ID: 2410769
    [Abstract] [Full Text] [Related]

  • 12. Ganglionic dopamine receptors as mediators of the inhibition of neurogenic vasoconstriction produced by fenoldopam.
    Lokhandwala MF, Sabouni MH.
    J Auton Pharmacol; 1985 Dec; 5(4):301-5. PubMed ID: 2869042
    [Abstract] [Full Text] [Related]

  • 13. Selective activation by LY-141865 and apomorphine of presynaptic dopamine receptors in the rat kidney and influence of stimulation parameters in the action of dopamine.
    Lokhandwala MF, Steenberg ML.
    J Pharmacol Exp Ther; 1984 Jan; 228(1):161-7. PubMed ID: 6694099
    [Abstract] [Full Text] [Related]

  • 14. Comparison of the effects of dopamine1- and dopamine2-receptor agonists on the cAMP generating system in canine coronary and renal arteries.
    Wang WZ, Zhao RR, Qin FZ.
    Methods Find Exp Clin Pharmacol; 1994 Dec; 16(10):691-6. PubMed ID: 7723468
    [Abstract] [Full Text] [Related]

  • 15. Effects of dopamine (DA) and SKF 82526, a selective DA1-receptor agonist, on vascular resistances in the canine forelimb.
    Grega GJ, Barrett RJ, Adamski SW, Lokhandwala MF.
    J Pharmacol Exp Ther; 1984 Jun; 229(3):756-62. PubMed ID: 6144791
    [Abstract] [Full Text] [Related]

  • 16. Pharmacological characterization of the receptor mediating electrophysiological responses to dopamine in the rat medial prefrontal cortex: a microiontophoretic study.
    Sesack SR, Bunney BS.
    J Pharmacol Exp Ther; 1989 Mar; 248(3):1323-33. PubMed ID: 2564893
    [Abstract] [Full Text] [Related]

  • 17. Evaluation of the effects of SKF 82526 and LY 171555 on presynaptic (DA2) and postsynaptic (DA1) dopamine receptors in rat kidney.
    Lokhandwala MF, Steenberg ML.
    J Auton Pharmacol; 1984 Dec; 4(4):273-7. PubMed ID: 6152269
    [Abstract] [Full Text] [Related]

  • 18. Facilitation of ganglionic transmission by sulpiride: evidence for an inhibitory role of dopamine in the canine sympathetic ganglion.
    Horn PT, Kohli JD, Goldberg LI.
    J Pharmacol Exp Ther; 1982 Nov; 223(2):462-8. PubMed ID: 6290639
    [Abstract] [Full Text] [Related]

  • 19. Effects of dopamine receptor activation on the level of cyclic AMP in the trabecular meshwork.
    Karnezis TA, Tripathi BJ, Dawson G, Murphy MB, Tripathi RC.
    Invest Ophthalmol Vis Sci; 1989 Jun; 30(6):1090-4. PubMed ID: 2567286
    [Abstract] [Full Text] [Related]

  • 20. Cardiovascular dopamine receptors: recent advances in agonists and antagonists of the DA1-receptor.
    Berkowitz BA, Ohlstein EH.
    J Cardiovasc Pharmacol; 1984 Jun; 6 Suppl 4():S559-63. PubMed ID: 6210423
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.